Twin Tissue. Tissue-based molecular analysis for solid tumours.

A 335-gene panel from FFPE or fresh tumour tissue.

Discuss the Tissue 335 pathway See the Twin workflow

Overview

What this pathway is

OnKommon Twin · Twin Tissue

335-gene panel. FFPE or fresh tumour tissue.

Twin Tissue analyses tumour tissue with a 335-gene panel, using either formalin-fixed, paraffin-embedded (FFPE) tissue — the way most biopsy samples are stored — or fresh tumour tissue.

Intended audience and use

Who it is for

People with solid tumours who have a suitable tissue sample, where the treating team considers targeted tissue profiling appropriate.

Sample and testing pathway

Sample and what is generated

Sample: FFPE or fresh tumour tissue.
Information generated: Findings across the 335-gene panel, with the biomarkers integrated into the Twin.

From result to Twin

How the information enters Twin

Tissue findings form the molecular foundation of the baseline Twin and are interpreted through the relevant layers, with the tissue's tumour content and quality recorded as context.

Analytical layers most relevant to this route

01 · Baseline — Day 0
Integrate the data. Build the Twin.
02 · During months 0–6
Review new findings inside the workflow.
03 · End of month 6
Review the evidence. Set the next pathway.
04 · After six months
Twin tracks
Track 12 Track 47 Track 118

Strengths

Why this route

Reads the tumour directly, from the sample most patients already have.
Works with FFPE — the way most biopsies are stored — or fresh tissue.
A focused 335-gene panel, sequenced deeply for sensitive detection.

How every finding is interpreted, from detection to decision

Deliverables

What you receive

A structured Twin report in the five documented components: executive molecular summary, molecular findings, treatment options to evaluate, clinical-trial matches and a longitudinal view.
Review and sign-off by the treating oncologist, within the KPCIRC sign-off process.
Entry into the six-month Twin journey, with the option to continue into a Twin track afterwards.

The treating oncologist owns every decision. Every Twin report is reviewed and signed by the treating oncologist, then taken to KPCIRC's Molecular Tumour Board.

KPCIRC sign-off process

Questions

Frequently asked questions

Can an older biopsy be used?

Sometimes, depending on its quality and tumour content. The laboratory assesses each sample before testing.

How does tissue testing relate to liquid biopsy?

Tissue testing analyses the tumour sample directly; liquid biopsy analyses tumour DNA shed into the blood. Each has its strengths, and the treating team chooses based on the clinical question.

What if there is not enough tissue?

Your treating team may discuss options such as a repeat biopsy or a plasma-based route.